

ASX RELEASE

Implementation of Scheme of Arrangement

Melbourne, Australia, 28 July 2020: [Sienna Cancer Diagnostics Limited \(ASX: SDX\)](#) (“Sienna” or “the Company”) is pleased to announce that the scheme of arrangement between Sienna and its shareholders (**Scheme**) in relation to the acquisition of all the shares in Sienna by BARD1 Life Sciences Limited (**BARD1**) was implemented today.

Implementation of the Scheme follows approval by shareholders on 15 July 2020 and approval of the Scheme by the Federal Court of Australia on 20 July 2020.

BARD1 share issue

Eligible former Sienna shareholders have been issued 13 new ordinary shares in BARD1 for every 5 Sienna shares they held as at the Scheme record date being 23 July 2020.

Under the Scheme, BARD1 has issued a total of 1,027,345,358 new ordinary shares in BARD1 to former Sienna shareholders as consideration for the transfer of their Sienna shares to BARD1.

Eligible former Sienna shareholders will be sent holding statements recording the number of new BARD1 shares issued to the holder under the Scheme

Changes to the BARD1 board of directors

As described in the Sienna Scheme Booklet released to the market on 12 June 2020, with effect from today:

- Dr Geoffrey Cumming and Ms Helen Fisher have been appointed as Non-Executive Chairman and Non-Executive Director of BARD1 respectively; and
- Mr Peter Lynton Gunzburg has resigned as Chairman of BARD1.

Changes to the Sienna board of directors

The following changes to the Board of Sienna will take effect from today:

- Mr Philip Powell has been appointed Non-Executive Director of Sienna.
- Mr Carl Stubbings and Mr Tony Di Pietro have resigned as Executive Directors of Sienna.

Removal from the Official List

Sienna intends to apply to be removed from the Official List of the ASX and for quotation of its shares to be terminated from 29 July 2020.

ENDS.

For Further Information, please contact:

Carl Stubbings, CEO & Managing Director
Sienna Cancer Diagnostics Ltd
cstubbings@siennadiagnostics.com.au
+61 3 9548 7586

The release of this announcement was authorised by Tony Di Pietro, Company Secretary.



About Sienna Cancer Diagnostics Ltd.

Sienna is a medical technology company that develops and commercialises diagnostic tests to assist in the early and accurate diagnosis of cancer, enabling improved treatment and patient outcomes. Sienna's first product, hTERT, a test that aids in the diagnosis of bladder cancer, has been launched and is being commercialised through a growing network of distribution partners globally.

Sienna entered the global liquid biopsy market in 2019 via the strategic acquisition of a "Molecular Net" technology called SIEN-NET™. The first commercial embodiment of SIEN-NET is EXO-NET™, which has been specifically designed to purify a patient sample for cancer-associated exosomes.

The Company recently announced the signing of an exclusive worldwide licence agreement with the University of Adelaide to develop and commercialise a unique cancer probe, SubB2M, which binds to a unique sugar molecule only present in human cancers and can detect its presence in the serum of cancer patients. SubB2M has the potential to detect cancer in a range of testing modalities such as liquid biopsies, immunoassays, circulating tumor cell assays and PET imaging.